Sionna Therapeutics, Inc. (SION)
NASDAQ:SION
Want to see SION full AI Analyst Report?
Top Page
Sionna Therapeutics, Inc.
(NASDAQ:SION)
Select Model
Select Model
Rating:55Neutral
Price Target:
$39.00
▼(-10.43% Downside)
Action:Reiterated
Date:04/16/26
The score is held back mainly by weak financial performance (no revenue, widening losses, and increasing cash burn), partially mitigated by a much stronger 2025 balance sheet and low leverage. Technicals are a meaningful positive, with the stock above key moving averages and positive momentum indicators, while valuation remains pressured due to losses and a negative P/E.
Positive Factors
Focused therapeutic strategy
Sionna's concentrated focus on small-molecule CFTR therapeutics creates a durable strategic position addressing a defined unmet medical need. Specialization supports deep scientific expertise, clearer clinical development priorities, and makes the company a natural partner or acquirer for larger firms seeking CF assets.
Negative Factors
Pre-revenue status with heavy cash burn
Being pre-revenue while burning significant cash is a durable structural risk: absent product sales or partnered revenue, the company must fund operations externally. This persistent burn increases dependency on capital markets or deals, constraining long-term autonomy and strategic options until commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused therapeutic strategy
Sionna's concentrated focus on small-molecule CFTR therapeutics creates a durable strategic position addressing a defined unmet medical need. Specialization supports deep scientific expertise, clearer clinical development priorities, and makes the company a natural partner or acquirer for larger firms seeking CF assets.
Read all positive factors
Sionna Therapeutics, Inc. (SION) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.78B
Dividend YieldN/A
Average Volume (3M)310.85K
Price to Earnings (P/E)―
Beta (1Y)1.13
Revenue GrowthN/A
EPS Growth-27.48%
CountryUS
Employees41
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.93
Shares Outstanding45,150,330
10 Day Avg. Volume362,732
30 Day Avg. Volume310,850
Financial Highlights & Ratios
PEG Ratio-0.64
Price to Book (P/B)5.36
Price to Sales (P/S)0.00
P/FCF Ratio-24.66
Enterprise Value/Market Cap0.97
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.82K
Enterprise Value/Ebitda-19.51
Forecast
1Y Price Target
$53.13Price Target Upside22.01% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)-2.57
Revenue Forecast (FY)N/A
Sionna Therapeutics, Inc. Business Overview & Revenue Model
Company Description
Sionna Therapeutics, Inc. is a biopharmaceutical company. The Company provides treatment paradigm for cystic fibrosis patients by developing medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator....
How the Company Makes Money
null...
Sionna Therapeutics, Inc. Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
56
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -453.00K | -647.00K | -668.00K | 0.00 | 0.00 |
| EBITDA | -88.59M | -88.33M | -69.89M | -49.75M | -41.25M |
| Net Income | -85.56M | -75.27M | -61.69M | -47.26M | -40.24M |
Balance Sheet | |||||
| Total Assets | 305.04M | 325.95M | 185.75M | 51.95M | 87.37M |
| Cash, Cash Equivalents and Short-Term Investments | 216.15M | 235.88M | 147.54M | 38.52M | 82.61M |
| Total Debt | 8.38M | 8.68M | 9.75M | 10.48M | 0.00 |
| Total Liabilities | 16.83M | 19.12M | 349.46M | 166.83M | 157.29M |
| Stockholders Equity | 288.21M | 306.83M | -163.71M | -114.88M | -69.92M |
Cash Flow | |||||
| Free Cash Flow | -72.14M | -66.67M | -52.81M | -44.81M | -37.94M |
| Operating Cash Flow | -71.85M | -66.30M | -52.79M | -43.70M | -36.07M |
| Investing Cash Flow | 47.27M | -118.75M | -126.91M | 27.35M | -29.26M |
| Financing Cash Flow | 5.21M | 205.71M | 178.97M | 31.00K | 110.86M |
Sionna Therapeutics, Inc. Risk Analysis
Sionna Therapeutics, Inc. disclosed 76 risk factors in its most recent earnings report. Sionna Therapeutics, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Sionna Therapeutics, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $1.78B | -16.81 | -27.31% | ― | ― | -27.48% | |
52 Neutral | $1.48B | ― | -53.31% | ― | 213.96% | 25.74% | |
52 Neutral | $3.05B | -16.50 | -41.54% | ― | 39.04% | 32.40% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $1.43B | ― | -55.68% | ― | ― | 51.42% | |
49 Neutral | $1.81B | ― | -48.84% | ― | -83.20% | -439.48% | |
47 Neutral | $1.50B | -4.88 | -45.47% | ― | -72.09% | -754.83% |
* Healthcare Sector Average
SION
Sionna Therapeutics, Inc.
39.50
26.00
192.59%
STOK
Stoke Therapeutics
30.30
20.82
219.57%
VIR
Vir Biotechnology
8.88
4.37
96.90%
IMTX
Immatics
11.22
6.10
119.14%
TNGX
Tango Therapeutics
21.08
19.19
1015.34%
AMLX
Amylyx Pharmaceuticals Inc
13.61
8.18
150.64%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.